Clinical trial

Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).

NCT05219500

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention FPI-2265 Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2021-12-16

PhasePHASE2

Conditions

Metastatic Castration Resistant Prostate Cancerunresolved

Interventions

FPI-2265DRUG

Sponsors & collaborators

Fusion Pharmaceuticals Inc.lead sponsor

Mapped research locations

HoustonTexas, United States1 OmahaNebraska, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05219500 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.